PDX Pharmaceuticals has received a Notice of Allowance for the third US patent for our ARAC™ technology. ARAC™ is based on our nanoparticle platform, Pdx-NP™, co-delivering antigen release agents and immune checkpoint inhibitors to create robust anti-tumor immune response.
First in the pipeline is ARAC-02™, which combines a PD-L1 antibody, a PLK1 inhibitor, and an immune-stimulant CpG to elicit a potent antitumor immune response, particularly through the activation of CD8+ T cells. This multifaceted approach has shown promising results in preclinical studies, with the potential to transform the landscape of lung cancer treatment.
With this latest patent allowance, we are not only extending our protection but also demonstrating our ongoing commitment to advancing our ARAC™ pipeline. We’re incredibly proud of this achievement and grateful for the support of our team and partners. Stay tuned for updates!